David Aebisher, PhD, DSc and Dorota Bartusik-Aebisher, PhD, DSc – Medical College of The University of Rzeszów, University of Rzeszów, Rzeszów, Poland

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000, MED062000
DOI: 10.52305/WGJA4563

This book provides a current review of the field of Trastuzumab pharmacology from a variety of chemical, biochemical, physiological, pharmacokinetical, pharmacodynamical, biophysical and medical perspectives. This book covers breast cancer treatment including current Trastuzumab therapy, radiation therapy and excision of tumors within the limits of healthy tissue. The text presents current knowledge and analysis of pertinent literature and knowledge. This book reports results from experimental models of HER2 oncogene overexpression and treatments which have been used in an effort to understand the relationship between HER2 and response to therapeutics.

In this book the HER2 oncogene has been extensively discussed as a prognostic factor and as a predictor of response to chemotherapy and endocrine therapy. The book includes data regarding the expression of HER2 oncogene in lung cancer and response to trastuzumab alone or in combination with chemotherapeutic agents. The interaction of HER2 with others drugs such as alkylating agents, platinum analogs and topoisomerase inhibitors, as well as additive interactions with taxanes, anthracyclines and some metabolites and antimetabolites are presented. Special cardiological supervision for patients with an increased risk of cardiotoxicity that have hypertension, ischemic heart disease, hypothyroidism or are heavy smokers during adjuvant trastuzumab therapy will also be reviewed.
(Imprint: Nova Medicine and Health)